NovaBridge Biosciences is a global biotechnology platform company dedicated to discovering and developing innovative therapeutics for oncology and ophthalmology. The company’s pipeline includes three clinical stage immuno oncology programs: givastomig a bispecific antibody targeting Claudin 18.2 and 4 1BB for gastric and other gastrointestinal cancers; uliledlimab a CD73 neutralizing antibody for solid tumors; and ragistomig a PD L1 and 4 1BB bispecific antibody for tumors resistant to checkpoint inhibitors. In ophthalmology the company advances VIS 101 a VEGF A and ANG 2 bispecific antibody for wet age related macular degeneration and diabetic macular edema through its wholly owned subsidiary Visara Inc. NovaBridge Biosciences maintains research and development sites in Rockville Maryland New Jersey California and Tianjin China and collaborates with partners such as ABL Bio and Bristol Myers Squibb to advance its candidates.

The company currently does not generate revenue from product sales. Its financial resources come from private placements equity offerings and strategic investments from partners. While it has entered into licensing and collaboration agreements these arrangements primarily involve payments made by the company to acquire rights or fund research rather than cash inflows. The company anticipates that future milestones royalties and potential product sales will become sources of revenue once its candidates receive regulatory approval and reach the market.

The company does not disclose separate operating segments in its filing. It manages its research development and commercialization activities as a single unified biotechnology platform. All therapeutic areas are overseen by the same leadership team and share common infrastructure and support functions.

NovaBridge Biosciences positions itself among emerging biotech firms that develop bispecific antibodies for solid tumors and retinal diseases. Its lead oncology candidate givastomig competes with approved therapies such as Zolbetuximab from Astellas and with experimental molecules from AstraZeneca Transcenta Sino Biopharmaceuticals and Innovent. In ophthalmology VIS 101 faces competition from established agents like aflibercept faricimab and from newer bispecific approaches being pursued by other companies. The company argues that its dual targeting strategy provides a broader patient reach than therapies that require high antigen expression and that its conditional activation of immune signaling may reduce systemic toxicity compared with conventional approaches.

The company’s intended customers are patients with gastric gastroesophageal pancreatic cancers and wet age related macular degeneration who receive treatment in hospitals oncology clinics and specialty eye care centers. These patients are cared for by medical oncologists gastroenterologists ophthalmologists and other health professionals. No specific customer names are disclosed in the filing because the therapies remain investigational and have not yet been commercialized.